FDA: Alzheimer's, Amyvid (florbetapir)
FDA Puts Early Alzheimer's Test on Hold
By Peggy Peck, Executive Editor
Published: March 18, 2011
"The FDA will not approve the novel contrast agent, florbetapir -- widely touted as a breakthrough for early diagnosis of Alzheimer's disease -- until manufacturer Eli Lilly puts a training program in place, the company announced."
Read the article.